Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations With Bromhexine, Higher Doses of Colchicine, and Hymecromone.

Autor:	Mondeshki T; Department of Propaedeutics of Internal Diseases, University Hospital Alexandrovska, Medical University-Sofia, Sofia, BGR., Bilyukov R; Department of Propaedeutics of Internal Diseases, University Hospital Alexandrovska, Medical University-Sofia, Sofia, BGR., Tomov T; COVID-19 Unit, University Hospital Alexandrovska, Sofia, BGR., Mihaylov M; Department of Pulmonary Disease, University Hospital Alexandrovska, Medical University-Sofia, Sofia, BGR., Mitev V; Department of Chemistry and Biochemistry, Medical University-Sofia, Sofia, BGR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Oct 13; Vol. 14 (10), pp. e30269. Date of Electronic Publication: 2022 Oct 13 (Print Publication: 2022).
DOI:	10.7759/cureus.30269
Abstrakt:	An otherwise healthy, 35-year-old man was hospitalized for the management of acute respiratory failure due to coronavirus disease 2019 (COVID-19)-related severe bilateral pneumonia and acute respiratory distress syndrome (ARDS). The patient therapeutic regimen included the widely accepted standard combination of oxygen, anticoagulation therapy; corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and antibiotics. A novel combination of colchicine, hymecromone, and bromhexine inhalations was added to the therapeutic regimen as part of our unique COVID-19 management institutional protocol. COVID-19-related severe bilateral pneumonia and acute respiratory distress syndrome (ARDS). The patient therapeutic regimen included the widely accepted standard combination of oxygen, anticoagulation therapy, corticosteroids, NSAIDs, and antibiotics. A novel combination of colchicine, hymecromone, and bromhexine inhalations was added to the therapeutic regimen as part of our unique COVID-19 management institutional protocol. Rapid clinical response on day 2, with a significant improvement of radiographic pulmonary changes on day 5, and improvement of laboratory results on days 5-7 were observed. The administration of inhalatory bromhexine in combination with high-dose colchicine and hymecromone was crucial for the positive outcome of the disease. This treatment regimen resulted in a four to five-fold decrease in the mortality of hospitalized patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Mondeshki et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu